Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis (Nasdaq: PSNL), a genomics company focused on cancer research, has scheduled the release of its Q2 2025 financial results for Tuesday, August 5, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day.
Investors can join via phone using the following dial-in numbers: 877-451-6152 (domestic) or 201-389-0879 (international). A webcast will be available in the Events section at investors.personalis.com, with a replay archived on the website after the call.
Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted an inducement stock option to its newly appointed Vice President, Corporate Controller. The option allows for the purchase of 100,000 shares of common stock at an exercise price of $6.31 per share, matching the closing price on July 15, 2025.
The stock option, granted under Personalis' 2020 Inducement Plan, follows a four-year vesting schedule with 25% vesting after one year and the remaining portions vesting monthly over the following three years, contingent on continued employment.
Personalis (Nasdaq: PSNL) has expanded and extended its strategic collaboration with Tempus AI through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test. The test will now cover breast, lung, and colorectal cancers, plus solid tumor immunotherapy monitoring.
The expansion follows promising interim results from the VICTORI study presented at AACR 2025, showing strong performance in detecting early CRC recurrence. The collaboration leverages Tempus' extensive network reaching over 50% of U.S. oncologists to accelerate the adoption of Personalis' ultra-sensitive cancer recurrence detection technology.
Personalis (NASDAQ: PSNL) announced multiple presentations at the upcoming ASCO Annual Meeting in Chicago, showcasing new clinical data for their NeXT Personal® ultrasensitive ctDNA assay. The presentations focus on detecting residual and recurrent cancer across various applications, including breast cancer and cervical cancer.
The company will present four studies: a clinical science symposium on circulating tumor DNA in breast cancer (PREDICT-DNA trial), an oral presentation on ctDNA detection in locally advanced cervical cancer (CALLA trial), and two poster presentations covering triple-negative breast cancer post-chemotherapy and immunotherapy monitoring in advanced cancer.
Personalis (NASDAQ: PSNL), a company specializing in advanced genomics for precision oncology, has announced its management team's participation in the upcoming Craig-Hallum 22nd Annual Investor Conference. The event is scheduled to take place on Wednesday, May 28, 2025, and will be held at The Depot Renaissance Hotel in Minneapolis, MN.
Personalis announced breakthrough results from their VICTORI cancer study, demonstrating that their NeXT Personal assay achieved 100% success in detecting colorectal cancer relapses before traditional imaging methods. The study, conducted at BC Cancer in Vancouver, analyzed blood samples from 71 patients with Stage I-IV colorectal cancer.
Key findings include:
- 100% detection rate of cancer recurrence before imaging confirmation
- 87% of relapses detected within 8 weeks post-surgery
- 85% of cases detected by 4 weeks post-surgery
- 100% accuracy in identifying disease-free patients
- Successful detection of distant metastases, including challenging lung metastasis
- 70% of initial detections were ultra-sensitive, with measurements as low as 2.45 PPM
The study, with a median follow-up of 15.75 months, highlights the potential of ctDNA-based liquid biopsies to help identify patients needing additional treatment while potentially helping others avoid unnecessary chemotherapy. The research continues as researchers aim to improve early cancer recurrence detection and treatment.
Personalis (Nasdaq: PSNL), a leader in advanced genomics for cancer, has scheduled the release of its first quarter 2025 financial results on Tuesday, May 6, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights.
Participants can join the call by dialing 877-451-6152 (domestic) or 201-389-0879 (international). The webinar will be accessible through the Events section on the company's investor website, with a replay available shortly after the call.